Compare Inovio Pharmaceuticals Inc (INO) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.4. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | VEA | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | — |
52-Week High | $2.87 | $72.89 |
52-Week Low | $0.66 | $58.19 |
Enterprise Value | $49.56M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
VEA trades at $73.30, up 1.1% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with recent buying from Ferguson Shapiro and selling from Financial Advisory Corp. Technical indicators show overbought RSI conditions while maintaining strong momentum with ADX at 47.42. The fund offers international diversification with a low expense ratio of 0.03% and upcoming dividend payment.
VEA presents a compelling international diversification opportunity with strong technical momentum and cost efficiency. However, overbought conditions and mixed institutional sentiment suggest potential near-term volatility. The fund's focus on developed markets outside the US provides geographic diversification but remains exposed to global economic headwinds and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
